Search results for "Adolescent"

showing 10 items of 6718 documents

Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry

2021

Epidemiology and potential risk factors for cystic fibrosis arthropathy (CFA) were studied in a relevant cystic fibrosis (CF) patient cohort.Cohort study of patients included in the German CF registry in 2016-2017. Descriptive analysis, exploratory tests and multivariable logistic regression were used to assess prevalence of CFA and associated potential risk factors for adult patients with/without chronic Pseudomonas aeruginosa infection.6069 CF patients aged from 0 to 78 years were analysed. CFA was observed in 4.9% of the patients. Prevalence was significantly higher in adult patients (8.4%) compared to patients18 years (0.7%; p0.0001). Logistic regression analyses in adult patients (n=33…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentCystic FibrosisCystic fibrosis-related diabetesmedicine.disease_causeLogistic regressionCystic fibrosisDiabetes ComplicationsSex FactorsRisk FactorsGermanyInternal medicineArthropathyEpidemiologyPrevalencemedicineHumansPseudomonas InfectionsRegistriesSinusitisChildAgedPseudomonas aeruginosabusiness.industryAge FactorsInfant NewbornInfantMiddle Agedmedicine.diseaseChild PreschoolPediatrics Perinatology and Child HealthCohortExocrine Pancreatic InsufficiencyFemaleJoint DiseasesbusinessCohort studyJournal of Cystic Fibrosis
researchProduct

The Revised Asthma Problem Behavior Checklist: Adaptation for Use in Spanish Asthmatic Patients

1997

Behavioral problems associated with asthma management were examined in a group of 100 adult Spanish outpatients with asthma (57 women, 43 men; 17-69 years of age). All of them completed a Spanish version of the Revised Asthma Problem Behavior Checklist (RAPBC). Data about duration, severity, and self-management of asthma (self-efficacy expectancies and health care utilization), as well as dyspnea and FEV1, were also recorded. The highest-reliability Cronbach alpha indices were for the criteria related to emotions and behaviors that could precipitate asthma attacks. Concurrent criterion validity was examined first by Pearson correlations between the RAPBC scores and clinical data about asthm…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentHealth BehaviorCronbach's alphaQuality of lifeSurveys and QuestionnairesHealth careCriterion validityHumansImmunology and AllergyAsthmatic patientMedicineAgedLanguageAsthmaAnalysis of VarianceBehaviorbusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseaseAsthmaChecklistrespiratory tract diseasesSelf CarePediatrics Perinatology and Child HealthPhysical therapyFemaleAnalysis of variancebusinessClinical psychologyJournal of Asthma
researchProduct

Lack of association of Aspergillus colonization with the development of bronchiolitis obliterans syndrome in lung transplant recipients: An internati…

2019

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is a major limitation in the long-term survival of lung transplant recipients (LTRs). However, the risk factors in the development of BOS remain undetermined. We conducted an international cohort study of LTRs to assess whether Aspergillus colonization with large or small conidia is a risk factor for the development of BOS.METHODS: Consecutive LTRs from January 2005 to December 2008 were evaluated. Rates of BOS and associated risk factors were recorded at 4 years. International Society of Heart and Lung Transplantation criteria were used to define fungal and other infections. A Cox proportional-hazards-model was constructed to assess the a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentInternational Cooperationmedicine.medical_treatmentBronchiolitis obliterans030230 surgeryCohort StudiesYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLung transplantationBOSCumulative incidenceRisk factorBronchiolitis ObliteransTransplantationbusiness.industryHazard ratioMiddle Agedcolonizationmedicine.diseasehumanitiesBOS; aspergillus; colonization; lung transplantation; risk factorsTransplantationAspergillus030228 respiratory systemCohortFemaleSurgeryCardiology and Cardiovascular MedicinebusinessLung TransplantationCohort studyThe Journal of Heart and Lung Transplantation
researchProduct

Gender Differences in Health‐Related Quality of Life Among Patients with Asthma

2004

This study has a twofold objective: 1) to explore to what extent suffering from asthma affects the HRQL of men and women differently at several stages of disease severity and 2) to analyze whether the informed poorer HRQL of asthmatic women is related to their higher scores on instruments measuring emotionally disordered symptoms. One hundred fifty-one outpatient asthmatics (84 women and 67 men) completed the Spanish versions of the Asthma Quality of Life questionnaire (AQL), as well as anxiety and depression inventories. A full history, physical examination, and pulmonary function test were performed on all subjects. Patients were classified into one of four asthma severity categories foll…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentPhysical examinationmacromolecular substancesSeverity of Illness IndexPulmonary function testingSex FactorsQuality of lifeSeverity of illnessmedicineHumansImmunology and AllergyDepression (differential diagnoses)AsthmaDepressive Disordermedicine.diagnostic_testbusiness.industryRespiratory diseaseMiddle Agedmedicine.diseaseAnxiety DisordersAsthmarespiratory tract diseasesDyspneaPediatrics Perinatology and Child HealthQuality of LifePhysical therapyAnxietyFemalemedicine.symptombusinessClinical psychologyJournal of Asthma
researchProduct

Metastasectomy With Standardized Lymph Node Dissection for Metastatic Renal Cell Carcinoma: An 11-Year Single-Center Experience

2013

Background Pulmonary metastasectomy (PM) for metastatic renal cell carcinoma is an established method of treatment for selected patients. The incidence of intrathoracic lymph node metastases (ITLNM) and outcomes remain controversial. The purpose of this study was to determine the incidence of ITLNM and long-term outcome of PM for metastatic kidney cancer. Methods From January 1999 to December 2009, 116 patients (82 men, age 61.7 ± 9.0 years) with metastases from kidney cancer underwent PM and systematic lymph node dissection with curative intent. Kaplan-Meier analyses, log-rank test, and Cox regression analyses were used to estimate survival and to determine prognosticators of survival. Res…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentThoracic CavityKaplan-Meier EstimateYoung AdultRenal cell carcinomaGermanymedicineHumansCarcinoma Renal CellLymph nodeAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overUnivariate analysisProportional hazards modelbusiness.industryMortality rateMetastasectomyMiddle Agedmedicine.diseaseKidney NeoplasmsIntrathoracic Lymph NodeSurgerySurvival Ratemedicine.anatomical_structureLymphatic MetastasisLymph Node ExcisionFemaleSurgeryMetastasectomyCardiology and Cardiovascular MedicinebusinessKidney cancerForecastingThe Annals of Thoracic Surgery
researchProduct

Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria

2010

Background Chronic spontaneous urticaria (CSU) lasting more than 6 weeks is one of the most disabling types of urticaria and often results in severely impaired quality of life. Patients with CSU are often unsatisfied with the standard treatment. Another treatment option recommended for patients with so-called nonresponding CSU according to the newest guidelines is intravenous immunoglobulin (IVIG). Objective To assess the efficacy and safety of high-dose IVIG as a treatment option in patients with therapy-resistant CSU. Methods Six patients with severe CSU unresponsive to other treatment options according to the newest guidelines for several weeks were treated with high-dose IVIG (2 g/kg ev…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentUrticariaImmunologyImmunoglobulin EQuality of lifeEdemaInternal medicineImmunopathologymedicineHumansImmunologic FactorsImmunology and AllergyAdverse effectAgedRetrospective Studiesbiologybusiness.industryStandard treatmentHeadacheImmunoglobulins IntravenousMiddle AgedSurgeryTreatment OutcomeBlood pressureChronic DiseaseHypertensionbiology.proteinItchingFemalemedicine.symptombusinessAnnals of Allergy, Asthma & Immunology
researchProduct

Does angioedema influence the quality of life in patients with chronic spontaneous urticaria?

2019

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectImmunologyMEDLINEEmbarrassmentSleep Initiation and Maintenance DisordersmedicineHumansImmunology and AllergyChronic UrticariaIn patientAngioedemaEmbarrassmentmedia_commonAngioedemabusiness.industryPruritusMiddle AgedMental Status and Dementia TestsDermatologyQuality of LifeFemalePolandmedicine.symptombusinessStress PsychologicalAnnals of Allergy Asthma & Immunology
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

2009

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting beta(2) agonists. Between 2005 and 2007 280 patients (58% female, mean age 44+/-16 yrs., 46% on oral corticosteroids, median serum IgE level 235IU/ml) who met the EU criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-marketing surveillance trial and were followed-up for 6 months. The median follow-up time was 195 days, the patients were treated with a median dose of 450mg omalizum…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyAdolescentAllergyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin ESeverity of Illness IndexYoung AdultQuality of lifeAdrenal Cortex HormonesForced Expiratory VolumeGermanyInternal medicineSeverity of illnessHypersensitivityHumansMedicineAnti-Asthmatic AgentsProspective StudiesChildProspective cohort studyAdverse effectAsthmaDose-Response Relationship Drugbiologybusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicSurgeryTreatment Outcomebiology.proteinFemaleIgETherapybusinessmedicine.drugRespiratory Medicine
researchProduct